Trial Profile
Phase II Trial for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Treated With Gliadel Followed by Concurrent Radiation Therapy, Temodar and Avastin, Then Followed by Avastin and Temodar Post-Radiation.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2019
Price :
$35
*
At a glance
- Drugs Carmustine polifeprosan 20 wafer (Primary) ; Bevacizumab; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 30 Jan 2019 Status changed from active, no longer recruiting to discontinued.
- 01 Feb 2018 Planned End Date changed from 1 Jun 2018 to 1 Jan 2019.
- 27 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Jun 2018.